AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16670899 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 12
Study 16670899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15579521 — intervention group
Group type: EXPERIMENTAL
Intervention: iothalamate GFR (iGFR)
Number of subjects: 1094
Study 15579521 — intervention group
Group type: COMPARATOR
Intervention: serum creatinine
Number of subjects: 1094
Study 11716797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (received instructions and examples)
Number of subjects: 39
Study 11716797 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no instructions)
Number of subjects: 39
Study 9395926 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (mean age 29 years)
Number of subjects: 216
Study 9395926 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (mean age 69 years)
Number of subjects: 216
Study 9395926 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-appraisal motivation in young adulthood
Number of subjects: 216
Study 9395926 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-appraisal motivation in later adulthood
Number of subjects: 216
Study 8136093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 to 90 mg/day)
Number of subjects: 24
Study 8136093 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR (240 to 480 mg/day)
Number of subjects: 24
Study 30030128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ghrelin
Number of subjects: 0
Study 30030128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30030128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ghrelin receptor inverse agonist (PF‐5190457)
Number of subjects: 0
Study 30030128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (females vs. males)
Number of subjects: 0
Study 30030128 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ghrelin
Number of subjects: 0
Study 26551765 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of patient comments along with standardized performance information
Number of subjects: 848
Study 26551765 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of patient comments
Number of subjects: 848
Study 25266222 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (weekly home visits with play demonstrations)
Number of subjects: 1420
Study 25266222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (daily micronutrient sprinkles)
Number of subjects: 1420
Study 25266222 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (psychosocial stimulation and micronutrient supplementation)
Number of subjects: 1420
Study 25266222 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1420
Study 21928096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin by IV bolus injection
Number of subjects: 100
Study 21928096 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 100
Study 20187772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (15% weight per volume; 3 g/kg BM) for 3 h after exercise
Number of subjects: 10
Study 20187772 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink after exercise
Number of subjects: 10
Study 20187772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion during early recovery from exercise‐induced muscle injury
Number of subjects: 10
Study 18028434 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 0
Study 18028434 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF + EPO
Number of subjects: 0
Study 16407697 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician referral to cardiac rehabilitation
Number of subjects: 304
Study 16407697 — intervention group
Group type: COMPARATOR
Intervention: Instruction to attend cardiac rehabilitation
Number of subjects: 304
Study 16407697 — intervention group
Group type: COMPARATOR
Intervention: Financial barriers to cardiac rehabilitation
Number of subjects: 304
Study 12918185 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg morphine sulfate p.o. approximately one hour before surgery
Number of subjects: 98
Study 12918185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10871971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 809
Study 10871971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 809
Study 10871971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times daily
Number of subjects: 809
Study 10871971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study 9095566 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education program on pain assessment and management
Number of subjects: 5
Study 9095566 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5
Study 8211024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg daily)
Number of subjects: 50
Study 8211024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3095913 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL 52694
Number of subjects: 15
Study 3095913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31412902 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Triple P for Baby plus care as usual
Number of subjects: 500
Study 31412902 — intervention group
Group type: EXPERIMENTAL
Intervention: Mellow Bumps plus care as usual
Number of subjects: 500
Study 31412902 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 500
Study 29395412 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressomassage (additional to standard physical therapy)
Number of subjects: 43
Study 29395412 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (control group)
Number of subjects: 43
Study 27825591 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized management of HF-REF
Number of subjects: 34
Study 27825591 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 34
Study 24812900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingtong Capsule (LC)
Number of subjects: 59
Study 24812900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 23192920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10(5) autologous CD34+ cells/kg (low-dose)
Number of subjects: 28
Study 23192920 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10(6) autologous CD34+ cells/kg (high-dose)
Number of subjects: 28
Study 23192920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study 20889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pronation (calcaneal eversion)
Number of subjects: 18
Study 20889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot supination (calcaneal inversion)
Number of subjects: 18
Study 20889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal leg rotation
Number of subjects: 18
Study 20889344 — intervention group
Group type: EXPERIMENTAL
Intervention: External leg rotation
Number of subjects: 18
Study 20889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg rotation
Number of subjects: 18
Study 17880771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 17880771 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 17880771 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study 15607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose buprenorphine (HD, 8‐8‐8‐4‐2 mg/day on days 1‐5)
Number of subjects: 30
Study 15607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose buprenorphine (LD, 2‐4‐8‐4‐2 mg/day on days 1‐5)
Number of subjects: 30
Study 15607843 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (C, 0.2‐0.3‐0.3‐0.2‐0.1 mg QID on days 1‐5)
Number of subjects: 30
Study 15607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose buprenorphine (HD)
Number of subjects: 30
Study 15607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose buprenorphine (LD)
Number of subjects: 30
Study 12653068 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue 0.2%
Number of subjects: 25
Study 12653068 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigo carmine 0.1%
Number of subjects: 25
Study 10405506 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25
Study 10405506 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 25
Study 7548807 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for 1 week (Group IIa, n = 16)
Number of subjects: 62
Study 7548807 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for 2 weeks (Group IIb, n = 17)
Number of subjects: 62
Study 7548807 — intervention group
Group type: COMPARATOR
Intervention: No drugs (Group I, n = 29)
Number of subjects: 62
Study 7548807 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (2 weeks) for patients whose ulcer recurred after nizatidine
Number of subjects: 62
Study 7548807 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of H. pylori infection
Number of subjects: 62
Study 2209512 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant bean flakes (174 g/d)
Number of subjects: 7
Study 2209512 — intervention group
Group type: COMPARATOR
Intervention: Potato flakes (102 g/d)
Number of subjects: 7
Study 6993442 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-course radiotherapy (two courses of 3000 rad in 2 weeks, separated by a 3-week rest period)
Number of subjects: 109
Study 6993442 — intervention group
Group type: COMPARATOR
Intervention: Continuous radiation therapy (30 fractions of 220 rad each, total dose of 6600 rad)
Number of subjects: 109
Study 31194785 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods (n = 16)
Number of subjects: 31
Study 31194785 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric control foods (n = 15)
Number of subjects: 31
Study 31194785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 28130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 188
Study 28130379 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 188
Study 28130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge hyponatremia
Number of subjects: 188
Study 28130379 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced hyponatremia
Number of subjects: 188
Study 26066390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous gel
Number of subjects: 8
Study 26066390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid fluid
Number of subjects: 8
Study 26066390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid vehicles
Number of subjects: 8
Study 26066390 — intervention group
Group type: COMPARATOR
Intervention: All products
Number of subjects: 8
Study 26066390 — intervention group
Group type: COMPARATOR
Intervention: Vehicle distribution
Number of subjects: 8
Study 26066390 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 8
Study 22874829 — intervention group
Group type: EXPERIMENTAL
Intervention: Association Splitting (AS)
Number of subjects: 49
Study 22874829 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 49
Study 20858487 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBW 2948 BS (EGFR kinase domain inhibitor), inhalatively administered
Number of subjects: 0
Study 20858487 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 20550864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric ropivacaine (15 mg)
Number of subjects: 117
Study 20550864 — intervention group
Group type: COMPARATOR
Intervention: Isobaric bupivacaine (10 mg)
Number of subjects: 117
Study 17885567 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) plus Routine Clinical Care (RCC)
Number of subjects: 94
Study 17885567 — intervention group
Group type: COMPARATOR
Intervention: Routine Clinical Care (RCC) alone
Number of subjects: 94
Study 14631220 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable silicone gastric banding (LASGB)
Number of subjects: 100
Study 14631220 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 100
Study 11435650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion in CPB
Number of subjects: 75
Study 11435650 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane through vaporiser in gas circuit of the CPB machine
Number of subjects: 75
Study 11435650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isoflurane inhalation (0.2-0.5%) + SNP in low doses (<1mg/kg/min)
Number of subjects: 75
Study 9322449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous RBC (washed)
Number of subjects: 36
Study 9322449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous RBC (unwashed)
Number of subjects: 36
Study 9322449 — intervention group
Group type: COMPARATOR
Intervention: Liquid-stored RBC
Number of subjects: 36
Study 9322449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (washed and unwashed)
Number of subjects: 36
Study 9322449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (all groups)
Number of subjects: 36
Study 9322449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved RBC (unwashed)
Number of subjects: 36
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.025 micrograms
Number of subjects: 0
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.125 micrograms
Number of subjects: 0
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 0.25 micrograms
Number of subjects: 0
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 1 microgram
Number of subjects: 0
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 at 250 micrograms
Number of subjects: 0
Study 8384887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH1-24 (various doses)
Number of subjects: 0
Study 3529909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg
Number of subjects: 18
Study 3529909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 18
Study 3529909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31167889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Rosiglitazone (M + R)
Number of subjects: 626
Study 31167889 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus Lifestyle (M + L)
Number of subjects: 626
Study 31167889 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 626
Study 27632886 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated (EU)
Number of subjects: 9
Study 27632886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydrated (HY)
Number of subjects: 9
Study 27632886 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EU and HY trials
Number of subjects: 9
Study 25409256 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute MRI
Number of subjects: 124
Study 25409256 — intervention group
Group type: COMPARATOR
Intervention: Control (2 weeks cast immobilization)
Number of subjects: 124
Study 23406619 — intervention group
Group type: COMPARATOR
Intervention: 80%C
Number of subjects: 24
Study 23406619 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%Caps
Number of subjects: 24
Study 23406619 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%P
Number of subjects: 24
Study 23406619 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%PCaps
Number of subjects: 24
Study 23406619 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%Caps, 80%P, 80%PCaps
Number of subjects: 24
Study 21195575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Self‐help program (CBS)
Number of subjects: 32
Study 21195575 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control group (WLC)
Number of subjects: 32
Study 19522133 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported education services (experimental group)
Number of subjects: 38
Study 19522133 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study 16712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 60
Study 16712621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations in the High group
Number of subjects: 60
Study 16712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain quality
Number of subjects: 60
Study 14979749 — intervention group
Group type: EXPERIMENTAL
Intervention: Valuation by feeling
Number of subjects: 0
Study 14979749 — intervention group
Group type: EXPERIMENTAL
Intervention: Valuation by calculation
Number of subjects: 0
Study 11172507 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.25% bupivacaine
Number of subjects: 12
Study 11172507 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.5% bupivacaine
Number of subjects: 12
Study 11172507 — intervention group
Group type: COMPARATOR
Intervention: Sham block
Number of subjects: 12
Study 9516191 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (C)
Number of subjects: 10
Study 9516191 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 10
Study 7995776 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group
Number of subjects: 48
Study 7995776 — intervention group
Group type: COMPARATOR
Intervention: No-Knowledge-of-Results (NKR) group
Number of subjects: 48
Study 7995776 — intervention group
Group type: COMPARATOR
Intervention: Random-Knowledge-of-Results (RKR) group
Number of subjects: 48
Study 7995776 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group (aware Ss)
Number of subjects: 48
Study 7995776 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-of-Results (KR) group (unaware Ss)
Number of subjects: 48
Study 3421201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU (50 micrograms) of vitamin D/d
Number of subjects: 0
Study 3421201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU (25 micrograms) of vitamin D/d
Number of subjects: 0
Study 3421201 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 0
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL‐apoB levels
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL‐apo(a) levels
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels in younger patients
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL‐apoB levels in younger patients
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: OxPL‐apo(a) levels in younger patients
Number of subjects: 220
Study 30476957 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multivariable adjustment
Number of subjects: 220
Study 26185392 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 108
Study 26185392 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional surgery)
Number of subjects: 108
Study 23518003 — intervention group
Group type: EXPERIMENTAL
Intervention: In-surgery bleaching with light activated 25% hydrogen peroxide gel followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Number of subjects: 22
Study 23518003 — intervention group
Group type: COMPARATOR
Intervention: In-surgery bleaching with 25% hydrogen peroxide without light activation followed by 2 weeks at home, night time bleaching with 10% carbamide peroxide gel in a customised bleaching tray.
Number of subjects: 22
Study 21502449 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption until intoxicated (study 1)
Number of subjects: 24
Study 21502449 — intervention group
Group type: COMPARATOR
Intervention: Abstaining from alcohol (study 1)
Number of subjects: 24
Study 21502449 — intervention group
Group type: EXPERIMENTAL
Intervention: Free alcohol consumption until intoxicated (study 2)
Number of subjects: 24
Study 19628185 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 2060
Study 16428497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) with aspirin (325 mg)
Number of subjects: 54
Study 16428497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) with ibuprofen (400 mg; 2 x 200 mg)
Number of subjects: 54
Study 16428497 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 54
Study 15447822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln + rhGH
Number of subjects: 60
Study 15447822 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 60
Study 15447822 — intervention group
Group type: COMPARATOR
Intervention: Gln
Number of subjects: 60
Study 11522769 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural-language-based entry system
Number of subjects: 16
Study 11522769 — intervention group
Group type: COMPARATOR
Intervention: Standard graphical user interface
Number of subjects: 16
Study 9237092 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Music (GIM) therapy
Number of subjects: 28
Study 9237092 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 28
Study 7954026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (ISDN) 40 mg twice daily
Number of subjects: 16
Study 7954026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16